- Home
- CALX vs VRNA Comparison
CALX vs VRNA Comparison
Compare CALX & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALX
- VRNA
- Stock Information
- Founded
- CALX 1999
- VRNA 2005
- Country
- CALX United States
- VRNA United Kingdom
- Employees
- CALX N/A
- VRNA N/A
- Industry
- CALX Telecommunications Equipment
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- CALX Consumer Discretionary
- VRNA Health Care
- Exchange
- CALX Nasdaq
- VRNA Nasdaq
- Market Cap
- CALX 2.4B
- VRNA 2.2B
- IPO Year
- CALX 2010
- VRNA 2017
- Fundamental
- Price
- CALX $29.31
- VRNA $35.66
- Analyst Decision
- CALX Strong Buy
- VRNA Strong Buy
- Analyst Count
- CALX 6
- VRNA 6
- Target Price
- CALX $42.50
- VRNA $43.83
- AVG Volume (30 Days)
- CALX 787.0K
- VRNA 1.1M
- Earning Date
- CALX 10-28-2024
- VRNA 11-04-2024
- Dividend Yield
- CALX N/A
- VRNA N/A
- EPS Growth
- CALX N/A
- VRNA N/A
- EPS
- CALX N/A
- VRNA N/A
- Revenue
- CALX $890,128,000.00
- VRNA $5,624,000.00
- Revenue This Year
- CALX N/A
- VRNA N/A
- Revenue Next Year
- CALX $3.13
- VRNA $554.09
- P/E Ratio
- CALX N/A
- VRNA N/A
- Revenue Growth
- CALX N/A
- VRNA 1127.95
- 52 Week Low
- CALX $26.76
- VRNA $11.39
- 52 Week High
- CALX $45.15
- VRNA $40.13
- Technical
- Relative Strength Index (RSI)
- CALX 22.12
- VRNA 51.76
- Support Level
- CALX $32.77
- VRNA $36.49
- Resistance Level
- CALX $34.13
- VRNA $40.13
- Average True Range (ATR)
- CALX 1.79
- VRNA 2.01
- MACD
- CALX -0.69
- VRNA -0.30
- Stochastic Oscillator
- CALX 3.90
- VRNA 47.60
About CALX Calix Inc
Calix Inc develops, market and sell Calix cloud, systems and software platforms to enable service providers of all types and sizes to innovate and transform. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.